Wu Yingtong, Che Yinggang, Zhang Yong, Xiong Yanlu, Shu Chen, Jiang Jun, Li Gaozhi, Guo Lin, Qiao Tianyun, Li Shuwen, Li Ou, Chang Ning, Zhang Xinxin, Zhang Minzhe, Qiu Dan, Xi Hangtian, Li Jinggeng, Chen Xiangxiang, Ye Mingxiang, Zhang Jian
Department of Pulmonary and Critical Care Medicine, Xijing Hospital, Air-Force Medical University, Xi'an, China.
First Sanatorium, Air Force Healthcare Center for Special Services, Hangzhou, China.
Front Genet. 2024 Jun 27;15:1293668. doi: 10.3389/fgene.2024.1293668. eCollection 2024.
INTRODUCTION: Observational investigations have examined the impact of glucosamine use on the risk of cancer and non-neoplastic diseases. However, the findings from these studies face limitations arising from confounding variables, reverse causation, and conflicting reports. Consequently, the establishment of a causal relationship between habitual glucosamine consumption and the risk of cancer and non-neoplastic diseases necessitates further investigation. METHODS: For Mendelian randomization (MR) investigation, we opted to employ single-nucleotide polymorphisms (SNPs) as instruments that exhibit robust associations with habitual glucosamine consumption. We obtained the corresponding effect estimates of these SNPs on the risk of cancer and non-neoplastic diseases by extracting summary data for genetic instruments linked to 49 varied cancer types amounting to 378,284 cases and 533,969 controls, as well as 20 non-neoplastic diseases encompassing 292,270 cases and 842,829 controls. Apart from the primary analysis utilizing inverse-variance weighted MR, we conducted two supplementary approaches to account for potential pleiotropy (MR-Egger and weighted median) and assessed their respective MR estimates. Furthermore, the results of the leave-one-out analysis revealed that there were no outlying instruments. RESULTS: Our results suggest divergence from accepted biological understanding, suggesting that genetically predicted glucosamine utilization may be linked to an increased vulnerability to specific illnesses, as evidenced by increased odds ratios and confidence intervals (95% CI) for diseases, such as malignant neoplasm of the eye and adnexa (2.47 [1.34-4.55]), benign neoplasm of the liver/bile ducts (2.12 [1.32-3.43]), benign neoplasm of the larynx (2.01 [1.36-2.96]), melanoma (1.74 [1.17-2.59]), follicular lymphoma (1.50 [1.06-2.11]), autoimmune thyroiditis (2.47 [1.49-4.08]), and autoimmune hyperthyroidism (1.93 [1.17-3.18]). In contrast to prior observational research, our genetic investigations demonstrate a positive correlation between habitual glucosamine consumption and an elevated risk of sigmoid colon cancer, lung adenocarcinoma, and benign neoplasm of the thyroid gland. CONCLUSION: Casting doubt on the purported purely beneficial association between glucosamine ingestion and prevention of neoplastic and non-neoplastic diseases, habitual glucosamine ingestion exhibits dichotomous effects on disease outcomes. Endorsing the habitual consumption of glucosamine as a preventative measure against neoplastic and non-neoplastic diseases cannot be supported.
引言:观察性研究已探讨了使用氨基葡萄糖对癌症和非肿瘤性疾病风险的影响。然而,这些研究的结果面临着因混杂变量、反向因果关系和相互矛盾的报告而产生的局限性。因此,有必要进一步研究习惯性摄入氨基葡萄糖与癌症和非肿瘤性疾病风险之间的因果关系。 方法:对于孟德尔随机化(MR)研究,我们选择使用单核苷酸多态性(SNP)作为与习惯性氨基葡萄糖摄入有强关联的工具。我们通过提取与49种不同癌症类型相关的基因工具的汇总数据,获得了这些SNP对癌症和非肿瘤性疾病风险的相应效应估计值,这些癌症类型包括378,284例病例和533,969例对照,以及20种非肿瘤性疾病,包括292,270例病例和842,829例对照。除了使用逆方差加权MR进行的主要分析外,我们还采用了两种补充方法来考虑潜在的多效性(MR-Egger和加权中位数)并评估它们各自的MR估计值。此外,留一法分析的结果表明没有异常的工具。 结果:我们的结果表明与公认的生物学理解存在差异,表明基因预测的氨基葡萄糖利用可能与对特定疾病的易感性增加有关,这在眼部和附件恶性肿瘤(2.47 [1.34 - 4.55])、肝/胆管良性肿瘤(2.12 [1.32 - 3.43])、喉良性肿瘤(2.01 [1.36 - 2.96])、黑色素瘤(1.74 [1.17 - 2.59])、滤泡性淋巴瘤(1.50 [1.06 - 2.11])、自身免疫性甲状腺炎(2.47 [1.49 - 4.08])和自身免疫性甲状腺功能亢进症(1.93 [1.17 - 3.18])等疾病的优势比和置信区间(95% CI)增加中得到证明。与先前的观察性研究相反,我们的基因研究表明习惯性氨基葡萄糖摄入与乙状结肠癌、肺腺癌和甲状腺良性肿瘤风险升高之间存在正相关。 结论:习惯性摄入氨基葡萄糖对疾病结局呈现出二分效应,这对氨基葡萄糖摄入与预防肿瘤性和非肿瘤性疾病之间所谓的纯粹有益关联提出了质疑。不能支持将习惯性摄入氨基葡萄糖作为预防肿瘤性和非肿瘤性疾病的措施。
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2025-6-20
Medicine (Baltimore). 2024-12-20
Cochrane Database Syst Rev. 2018-1-29
J Integr Complement Med. 2023-8
Cancer Epidemiol Biomarkers Prev. 2023-4-3
Pharmacoepidemiol Drug Saf. 2022-12
Ther Adv Musculoskelet Dis. 2022-7-26
Cancer Epidemiol Biomarkers Prev. 2022-3-1